Kallikrein-related peptidases: mechanistic understanding for potential therapeutic targeting in cancer.

Autor:	Daneva GN; Department of Biochemistry and Molecular Biology, National and Kapodistrian University of Athens, Athens, Greece., Tsiakanikas P; Department of Biochemistry and Molecular Biology, National and Kapodistrian University of Athens, Athens, Greece., Adamopoulos PG; Department of Biochemistry and Molecular Biology, National and Kapodistrian University of Athens, Athens, Greece., Scorilas A; Department of Biochemistry and Molecular Biology, National and Kapodistrian University of Athens, Athens, Greece.
Jazyk:	angličtina
Zdroj:	Expert opinion on therapeutic targets [Expert Opin Ther Targets] 2024 Oct; Vol. 28 (10), pp. 875-894. Date of Electronic Publication: 2024 Oct 21.
DOI:	10.1080/14728222.2024.2415014
Abstrakt:	Introduction: Human kallikrein-related peptidases (KLKs) represent a subgroup of 15 serine endopeptidases involved in various physiological processes and pathologies, including cancer. Areas Covered: This review aims to provide a comprehensive overview of the KLK family, highlighting their genomic structure, expression profiles and substrate specificity. We explore the role of KLKs in tumorigenesis, emphasizing their potential as biomarkers and therapeutic targets in cancer treatment. The dysregulated activity of KLKs has been linked to various malignancies, making them promising candidates for cancer diagnostics and therapy. Expert Opinion: : Recent advancements in understanding the mechanistic pathways of KLK-related tumorigenesis offer new prospects for developing targeted cancer treatments. Expert opinion suggests that while significant progress has been made, further research is necessary to fully exploit KLKs' potential in clinical applications.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu